Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review

BACKGROUND: Individuals with chronic kidney disease (CKD) are at a very high risk for atherosclerotic cardiovascular disease (ASCVD). New lipid-lowering agents offer hope of improved outcomes where traditional agents have been less efficacious, yet the cost of these agents needs consideration in thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallagher, Alexandra, Agresta, Blaise, Smyth, Brendan, Jardine, Meg, Ferro, Charles, Morton, Rachael L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
CKJ Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155226/
https://www.ncbi.nlm.nih.gov/pubmed/35664276
http://dx.doi.org/10.1093/ckj/sfab288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155226/
https://www.ncbi.nlm.nih.gov/pubmed/35664276
http://dx.doi.org/10.1093/ckj/sfab288

Ejemplares similares